Maxim Group analyst Jason McCarthy maintained a Buy rating on OncoSec Medical (NASDAQ: ONCS) today and set a price target of $5. The company’s shares opened today at $1.61.
McCarthy wrote:
“OncoSec announced expansion of the relationship with Merck (MRK – NR) to evaluate the combination of TAVO (intratumoral DNA-based IL-12) + Cancer (TNBC). A P2 study (KEYNOTE-890) is planned and we expect the trial to initiate in mid-2018..”
According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.5% and a 38.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Currently, the analyst consensus on OncoSec Medical is Moderate Buy and the average price target is $4.50, representing a 179.5% upside.
In a report issued on April 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $4 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.95 and a one-year low of $0.88. Currently, OncoSec Medical has an average volume of 1.16M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications. The company was founded by Avtar S. Dhillon, Punit S.
